IPO Issue Details
Issue Price / Price Band₹126 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size119 Shares per Lot
Total Issue Size1,00,00,000 shares (aggregating up to ₹126.00 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenMon, 01 Sep 2025
Subscription CloseWed, 03 Sep 2025
Anchor AllotmentFri, 29 Aug 2025
Basis of AllotmentThu, 04 Sep 2025
Initiation of RefundsMon, 08 Sep 2025
Credit of Shares to DematMon, 08 Sep 2025
Listing DateTue, 09 Sep 2025
UPI Mandate Deadline2025-09-03
Application & Investment Details
Retail — Min (1 Lots)₹14,994 — 119 shares
Retail — Max (13 Lots)₹194,922 (13 Lots)
HNI — Min (14 Lots)₹2,09,916 — 1,666 shares
EPS (Pre-IPO)₹3.64
EPS (Post-IPO)₹2.70
P/E Ratio (Pre-IPO)34.59x
P/E Ratio (Post-IPO)46.59x
Pre-IPO Promoter Holding2,88,29,351 shares
Post-IPO Promoter Holding3,88,29,351 shares
About Amanta Healthcare Ltd.
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products, specifically parenteral products, which are packaged in plastic containers utilizing Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technologies. The company is also a manufacturer of medical devices.The company manufactures fluid therapy formulations, including IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also offers irrigation solutions, first-aid products, and eye lubricants in the medical device segment.The company markets products through three business units:National sales,International sales andProduct partnering with various foreign and Indian pharmaceutical companies.The company manufactures over 45 generic products, marketing them under their brands in India through 320 distributors and stockists.The company sells products in Africa, Latin America, the UK, and beyond. Its products are registered in 19 countries and comply with various regulations. In Fiscal 2025, the company exported branded products to 21 countries.As of March 31, 2025, the company has a team of 1,718 employees at its formulation and development and quality laboratory.Competitive StrengthsWell-established manufacturer of pharmaceutical formulations with a diverse product portfolio and diverse market.Large manufacturing capabilitiesWide Domestic and International Marketing Network.Experienced management team supported by a large, diverse and skilled workforce.
Objects of the Issue
Amanta Healthcare Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat
70.00
2
2 Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat
30.13
3
3 General corporate purposes
6.60
Shareholding & Lock-in
Pre-IPO Promoter Holding
2,88,29,351 shares
Post-IPO Promoter Holding
3,88,29,351 shares
Lock-in Period (30%)October 3, 2025
Lock-in Period (50%)December 2, 2025